
|Articles|October 31, 2022
Massive Bio Onboards Over 100,000 Cancer Patients
Advertisement
Massive Bio announced that the company exceeded its goal to onboard 100,000 cancer patients in its platform by the end of 2022. The Massive Bio platform matches cancer patients with relevant clinical trials using AI.
Read more about the platform and its enrollment
.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation
2
Operational Pragmatism in ePRO-heavy trials
3
How Selective Safety Data Collection Could Make Pragmatic Trials Scalable
4




